A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multinational, Phase IIb Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at 3 Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
Sponsor: AstraZeneca
A PHASE2 clinical study on Chronic Obstructive Pulmonary Disease, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 9 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE2
-
Jan 2026 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Mar 2026 [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jul 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Antigonish Nova Scotia, Canada , Anyang, South Korea , Asahikawa, Japan , Bardejov, Slovakia , Barnaul, Russia , Berlin, Germany , Boerne, United States , Bojnice, Slovakia , Bratislava, Slovakia and 95 more locations